Polarean Imaging (POLX ) has secured its first Xenon MRI research system installation in Asia, with National Taiwan University Hospital (NTUH) in Taipei agreeing to take a Xenon Hyperpolariser through the company’s strategic partner Philips.
The system will be supplied via Philips Medical Systems Nederland, extending an existing collaboration between Polarean and Philips to bring functional lung MRI into leading academic centres.
NTUH is widely regarded as Taiwan’s premier academic medical centre, with a strong record in clinical research and advanced patient care, making it a key reference site for Xenon MRI in the region.
Polarean’s newly appointed Taiwanese distributor, Sumtage Enterprise Company, will support installation and training at NTUH, and will work with Polarean on the processes required to secure regulatory approval and reimbursement in Taiwan.
This agreement marks Polarean’s first entry into Asia and is described by the company as an important step in laying the groundwork for broader regional adoption of Xenon MRI technology.
Polarean’s CEO Christopher von Jako, Ph.D. said: "This first Xenon MRI system in Taiwan, supported by Philips and Sumtage, marks an important milestone in our international strategy. The National Taiwan University Hospital is the country's premier academic medical centre, and this order highlights the recognition of Xenon MRI's potential in lung health. Together with Sumtage, we will focus on ensuring successful installation and training at NTUH while also advancing the regulatory and reimbursement pathways needed for broader adoption in Taiwan."
View from Vox
Polarean’s first Xenon MRI system in Asia gives it an early foothold in a key imaging market, supported by a leading hospital partner and its long-running collaboration with Philips. If NTUH can help demonstrate clinical and economic value, this collaboration could accelerate regulatory progress and open the door to wider regional uptake of Xenon lung MRI.